The Latest Breaking News from biotechnology

Biotechnology company Bavarian Nordic expects to sign more contracts for its vaccine against monkeypox after "overwhelming" interest from governments around the world, its management told investors on Tuesday.

Scotland’s industrial biotechnology community is exceeding growth expectations and is on track to achieve annual turnover of £1.2bn by 2025,…

Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech (NYSE: XBI) peaked in February 2021 and is now 60% lower than its all-time high price ($174.79 vs. $66.50).

Key Takeaways: Boan Biotechnology sells only one product so far and is facing stiff competition from other similar drugs Luye Pharma bought Boan in 2020 and is taking it public at a time when markets are bearish By Molly Wen

In nanoscience, nanotechnology and biotechnology

Panacea Plant Sciences, a Washington State biotechnology company, has discovered formulations that act synergistically with dimethyltryptamine (DMT). The company announced the findings during the Cannabis Science Conference, on May 19.

The guidelines circumvent challenges of using foreign genes to change crops profile

AstraZeneca plc (NASDAQ:AZN) moved to bolster its COVID-19 portfolio of antibodies with a $157 million licensing deal for experimental therapies developed by newly-launched UK-based biotech, RQ Biotechnology Ltd. In addition to the initial sum, AstraZeneca will pay possible royalty payments as part of the exclusive license to develop pre-clinical COVID antibodies engineered by RQ…

Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125 (from $200) on Vir Biotechnology Inc (NASDAQ:VIR). The analyst maintained a Buy rating on VIR shares. The analyst continues to view Vir's platform, validated with successful antiviral therapies against Ebola and COVID-19, and pipeline,…